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RESEARCH ARTICLE Open Access
Use of imaging biomarkers to assess perfusion
and glucose metabolism in the skeletal muscle of
dystrophic mice
Nabeel Ahmad1,2,3, Ian Welch4, Robert Grange5, Jennifer Hadway1,2, Savita Dhanvantari1,3, David Hill1,
Ting-Yim Lee1,2,3,6 and Lisa M Hoffman1,3,7*
Abstract
Background: Duchenne muscular dystrophy (DMD) is a severe neuromuscular disease that affects 1 in 3500 boys. The
disease is characterized by progressive muscle degeneration that results from mutations in or loss of the cytoskeletal
protein, dystrophin, from the glycoprotein membrane complex, thus increasing the susceptibility of contractile muscle
to injury. To date, disease progression is typically assessed using invasive techniques such as muscle biopsies, and while
there are recent reports of the use of magnetic resonance, ultrasound and optical imaging technologies to address the
issue of disease progression and monitoring therapeutic intervention in dystrophic mice, our study aims to validate the
use of imaging biomarkers (muscle perfusion and metabolism) in a longitudinal assessment of skeletal muscle
degeneration/regeneration in two murine models of muscular dystrophy.
Methods: Wild-type (w.t.) and dystrophic mice (weakly-affected mdx mice that are characterized by a point mutation
in dystrophin; severely-affected mdx:utrn-/- (udx) mice that lack functional dystrophin and are null for utrophin) were
exercised three times a week for 30 minutes. To follow the progression of DMD, accumulation of 18 F-FDG, a measure
of glucose metabolism, in both wild-type and affected mice was measured with a small animal PET scanner (GE eXplore
Vista). To assess changes in blood flow and blood volume in the hind limb skeletal muscle, mice were injected
intravenously with a CT contrast agent, and imaged with a small animal CT scanner (GE eXplore Ultra).
Results: In hind limb skeletal muscle of both weakly-affected mdx mice and in severely-affected udx mice, we
demonstrate an early, transient increase in both 18F-FDG uptake, and in blood flow and blood volume. Histological
analysis of H&E-stained tissue collected from parallel littermates demonstrates the presence of both inflammatory
infiltrate and centrally-located nuclei, a classic hallmark of myofibrillar regeneration. In both groups of affected
mice, the early transient response was succeeded by a progressive decline in muscle perfusion and metabolism;
this was also evidenced histologically.
Conclusions: The present study demonstrates the utility of non-invasive imaging biomarkers in characterizing
muscle degeneration/regeneration in murine models of DMD. These techniques may now provide a promising
alternative for assessing both disease progression and the efficacy of new therapeutic treatments in patients.
Background
Duchenne muscular dystrophy (DMD) is a severe reces-
sive X-linked neuromuscular disease that affects 1 in
3500 live-male births. The disease is characterized by
progressive skeletal muscle degeneration that arises due
to mutations in or loss of dystrophin from the dystro-
phin-glycoprotein complex (DGC) within the sarcolem-
mal membrane [1,2]. Dystrophin deficiency destabilizes
the sarcolemma, and not only renders myofibers suscep-
tible to contraction-induced damage [1,2], but also
allows cytosolic Ca2+ levels to increase, and initiates a
cascade of intracellular events that lead to necrosis [3,4].
Skeletal muscle cell signaling is further affected through
the mislocalization of neuronal nitric oxide synthase
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(nNOS) that is normally localized to the sarcolemma as
part of the DGC [5-7]. Typically, this DGC protein plays
a role in myofiber differentiation [8], modulation of con-
tractile force [9], and exercise-induced glucose uptake
[10]. In DMD, however, nNOS mislocalization has been
shown to produce ischemia that, in conjunction with
membrane leakage and necrosis, triggers an inflamma-
tory reaction [11]. Histological analyses reveal necrotic
or degenerating myofibers that are surrounded by
macrophages and CD4+ lymphocytes [11].
While a diagnosis of DMD is usually made in patients
approximately 5 years of age by assessment of family
history and PCR genotyping [12], analysis of disease
progression typically relies upon the measurement of
muscle strength [13], creatine kinase levels [14] and
painful, invasive muscle biopsies [15]. Previous studies
have reported the use of magnetic resonance (MR) ima-
ging to detect changes in muscle architecture [16] or
sarcolemmal permeability [17] in dystrophic mice. Posi-
tron emission tomography (PET) has also been used to
measure metabolic differences in myocardia of healthy
wild-type (w.t.) versus mdx mice [18]. To date, however,
there is no effective method to reliably and non-inva-
sively assess degenerative changes that occur as DMD
progresses, particularly the ischemic, metabolic and
inflammatory changes that occur as a result of aberrant
sarcolemmal signaling. There is also a clear unmet med-
ical need to establish accurate monitoring of cell-based
and other therapies, including exercise, for the treat-
ment of muscle disease. Therefore, in the present study,
we demonstrate the utility of dynamic contrast
enhanced computed tomography (DCE-CT) and PET
scanning to, firstly, longitudinally assess changes in mus-
cle perfusion and metabolism as disease progresses in
two murine models of DMD, and to, secondly, provide a
baseline for monitoring the success (or failure) of var-
ious therapeutics.
Methods
Animal Models of Duchenne Muscular Dystrophy
Male wild-type (C57BL/6) and mdx (point mutation in
dystrophin) mice were purchased from Charles River
and Jackson Laboratories, respectively. Mdx:utrn hetero-
zygote mice (generously provided by Robert Grange,
Virginia Polytechnic Institute and State University,
although originally generated by Mark Grady and Josh
Sanes at Washington University, St. Louis,) were bred to
generate mdx: utrn-/- (udx) mice lacking both utrophin
and functional dystrophin. Only male mice were used in
this study. Four groups of mice were used for imaging:
1) control wild-type (w.t. n = 9), which were exercised
involuntarily, as described below; 2) exercised mdx (n =
9); 3) non-exercised mdx (n = 9); and 4) non-exercised
udx (n = 11). The same four groups consisting of three
mice in each were used for histology at time points spe-
cified below. All study procedures were approved by our
institutional Animal Ethics Committee and conducted
according to guidelines set by the Canadian Council on
Animal Care.
Exercise and Non-exercise protocol
Mdx and w.t. mice in the exercised group ran 3 times
weekly for 30 minutes each time on a motorized tread-
mill (Accuscan Instruments), at a speed of 15 meters
per minute (mpm) and a 7-degree uphill incline [19].
This regime was initiated when mice were 6 weeks of
age, and continued until animals were 22 weeks of age.
Due to the severity of their disease state, udx mice were
unable to tolerate the exercise protocol, and as such, no
exercise group was employed. A non-exercised w.t.
group was also not employed in this study because our
experimental design was to investigate the effect of
chronic involuntary exercise on muscle degeneration/
regeneration in dystrophic mouse models. To ensure
that all animals in the study were handled similarly,
non-exercised mdx and udx mice were walked on the
treadmill 3 times weekly, for 10 minutes each time at 5
- 7mpm with no incline. Exercised animals began run-
ning 45 minutes prior to scans, and all groups allowed
15 minutes of rest before anesthetic induction. An addi-
tional 10-15 minutes was required for placement of a
tail vein catheter for delivery of both contrast for DCE-
CT scanning and for radiolabeled glucose substrate for
PET scanning.
DCE-CT and PET Imaging
To obtain baseline values, all mice were imaged using
DCE-CT and PET at 6 weeks of age, prior to the initia-
tion of either the exercise or non-exercise protocol. The
mice were thereafter imaged biweekly for another 16
weeks up to 22 weeks of age. During each imaging ses-
sion, anesthesia was induced with 3-4% isofluorane and
then maintained with a 1.5% oxygen-balanced isofluor-
ane mixture, delivered at a constant rate of 1L/min. All
imaging attempted to focus on the gastrocnemius mus-
cle (GM) of the hind limb since the size of the GM rela-
tive to other skeletal muscles in the posterior
compartment of the hind limb (HL) allows for greater
visibilility in longitudinal DCE-CT and PET images, and
thus more consistent placement of regions of interest
(ROIs); realistically, placement of ROIs included several
muscles within the posterior compartment of HL mus-
culature (Figure 1). Data acquired for each mouse over
the course of the study were normalized with respect to
baseline values for each mouse to minimize biological
variability between different mice, thus allowing us to
assess longitudinal changes between different groups of
mice.
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(a)DCE-CT Scanning for Measurement of Muscle Blood
Flow and Blood Volume
A 4 cm thick slab of both hind limbs, including the
GMs, separated into forty 0.9 mm thick slices at 175 µm
resolution, was scanned repetitively with a GE Health-
care eXplore Locus Ultra µCT scanner. The 5 minute
scan duration was divided into two phases: first, 1 s
scan for 30 s and then one 1 s scan every 15 s for the
remainder of the scan duration. Five seconds into the
first phase of scanning, contrast agent (150 μL of diluted
Hypaque 300, 200 mg of iodine per ml) was injected via
a tail vein catheter at an injection rate of 2.0 ml/min
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Figure 1 DCE-CT image (a), Blood flow (b), Blood volume (c) and FDG-PET image (d) of a mdx mouse at 8 weeks of age. Axial slices
using DCE-CT of the lower limbs of a dystrophic mouse (a,b,c); coronal slice generated using PET, displaying the mdx mouse from the
abdomen to the feet (d). Red circles indicate one region of interest (ROI) encompassing the posterior compartment of the hind limb (HL)
musculature from which data was collected.
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with an infusion pump (New Era Pump Systems Inc)
that was triggered by the CT scanner. We used CT Per-
fusion software (GE Healthcare) to describe the
exchange of contrast between the blood stream and the
interstitial space to quantify blood flow (BF) and blood
volume (BV) [20,21], and to calculate functional maps of
these parameters from the acquired series of CT images
[21] in healthy versus degenerating/regenerating muscle
[22]. The tracer kinetics model used to calculate BF and
BV maps is described in full in the Appendix. From the
derived BF and BV maps, mean BF and BV in the HL
musculature of a CT slice were derived by ROI analysis
(Figure 1). Values from all slices of a mouse were
weighted according to area and averaged, and the aver-
aged values normalized by the corresponding baseline
values. Results from mice respective to their own group
and week were then averaged.
(b)PET Scanning for Measurement of Glucose Metabolism
A small dose of a glucose analog, fluorine-18 labeled
fluorodeoxyglucose (18F-FDG, 11-38 MBq), was adminis-
tered via a tail vein catheter. Forty to sixty minutes after
injection, HL musculature were imaged with a small ani-
mal PET scanner (GE Healthcare, eXplore Vista DR),
using a photopeak window of 250-700 keV for a dura-
tion of 30 minutes. The acquired data were corrected
for scatter and reconstructed using an OSEM algorithm
into twenty-six, 1.7 mm thick slices at a transaxial reso-
lution of 1.6 mm. The (sensitivity) factor for converting
counts in reconstructed PET images to activity (in MBq)
was determined at regular intervals by scanning with the
PET scanner a 5 cm diameter water phantom filled with
a known amount of F-18 activity (11-14 MBq). ROIs
were drawn in coronal PET slices to encompass the pos-
terior HL skeletal muscle compartment including the
GM (Figure 1). Values from all slices of a mouse were
weighted according to area and averaged. The average
count for the HL muscle was converted into mean activ-
ity per ml using the conversion factor determined above,
then normalized by the injected activity and the body
weight of the animal to arrive at the standardized uptake
value (SUV), a semi-quantitative indicator of the average
glucose metabolic rate over the period from injection to
measurement [23,24]. The SUVs were normalized by the
baseline value for each mouse, and the normalized
values then averaged respective to week and group.
Histological analysis
Twelve extra mice were added to each of the above-
mentioned 4 groups of mice, for sacrifice at baseline (6
weeks) and at 8, 14, and 22 weeks of age. Mice used for
histology were handled and exercised in the same man-
ner as imaged mice. For udx mice that did not survive
up to 22 weeks of age, the GMs were harvested for
histology at the time of their death, typically between
20-22 weeks of age. Following harvest, GMs were fixed
in 10% neutral-buffered formalin for a minimum of 48
hours. The fixed muscle was then embedded in paraffin
wax and cut transversely in 5-micron sections for subse-
quent staining with haematoxylin and eosin (H&E) [25].
Stained sections were evaluated for histological features
characteristic of DMD, including fiber degeneration,
fiber regeneration, hypercontracted fibers, myophagia,
inflammatory infiltrate, fibrosis and necrosis. Whereas
eccentric nuclei are typical of healthy myofibers, fibers
that contain centralized nuclei are evidence of a regen-
erative process, thus reflecting a state in which resident
muscle satellite cells differentiate into mature myocytes
that engraft within damaged myofibers to initiate repair
[26,27].
Data analysis
Statistical analyses were performed using the SPSS Sta-
tistics software package for Windows (SPSS Inc., V15.0).
Repeated measures ANOVA was used as an omnibus
test to identify significant differences in normalized BF
and BV, and SUV of 18F-FDG in the HL musculature
among groups and time points within groups. Tukey
tests were used for the post-hoc analyses of differences.
Results
Survival of mice in experimental groups
Kaplan Meier survival curves illustrate that there were
significant differences in the survival rates of severely-
affected udx mice relative to mice in each of the other
three experimental groups (Figure 2). Specifically, 67%,
67%, 56% and 0% of mice in the exercised wild-type (w.
t.), non-exercised mdx, exercised mdx and non-exer-
cised udx groups, respectively, survived until the termi-
nation of the study.
Early changes in perfusion, metabolism and histology
following exercise
Absolute values of muscle perfusion (BF and BV), and
glucose metabolic rate (SUV) measured at baseline for
w.t., non-exercised mdx, exercised mdx and udx mice
are provided in Table 1. As illustrated in Figure 3, nor-
malized blood flow (NBF) and blood volume (NBV) in
the HL musculature of healthy exercised w.t. mice did
not change significantly from the initiation of the study
at baseline to its termination. In each of the other 3
experimental groups, however, both NBF and NBV
peaked 2 weeks post-baseline (8 weeks of age); specifi-
cally, mice in the non-exercised mdx group, the exer-
cised mdx group, and the udx group exhibited an 18%,
38% and 42% increase in NBF above baseline, respec-
tively (P < 0.05). Each experimental group exhibited
similar changes in NBV, with a 40%, 79% and 97%
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increase above baseline observed in non-exercised mdx,
exercised mdx and udx mice, respectively (P < 0.05).
Significant differences in NBF and NBV were also
observed between both mdx groups and the udx group,
between non-exercised mdx and their exercised litter
mates, and between all 3 groups and w.t. mice (P <
0.05).
Analysis of glucose uptake, as assessed by normalized
18F-FDG SUV (NSUV) in the HL musculature of mice
in each of the four experimental groups of mice revealed
patterns similar to those observed for NBF and NBV
(Figure 4). Specifically, at 4 weeks post-baseline (10
weeks of age), NSUVs in non-exercised and exercised
mdx mice were higher than that observed in w.t. mice
(P < 0.05), exhibiting 31% and 50% increases above
baseline values, respectively. Severely-affected udx mice,
in contrast, exhibited a pronounced peak in NSUV two
weeks post-baseline. This value is higher than that of
the w.t. mice (P <0.05) and represents a 62% increase
above its baseline (P <0.05).
Analysis of H&E-stained GM tissue sections revealed
that, at baseline (6 weeks of age) and at all time points
thereafter, the GMs of w.t. mice were predominantly
comprised of eccentrically-located nuclei (arrow), were
devoid of inflammatory cells, and displayed normal
amounts of connective tissue amongst myofibers (Figure
5a). In contrast, the GMs harvested from either group
of mdx mice (non-exercised and exercised) at baseline
exhibited numerous centrally-located nuclei (open arrow
head), and small amounts of inflammatory infiltrate
(arrow head) in the interstitial space (Figure 5b &5c(i)).
The severity of the degenerative process in udx mice,
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Figure 2 Kaplan Meier survival curve of mice used in study. Four experimental groups of mice were used in the longitudinal study after
initiation of exercise regime: exercised wild-type (W.T.-Ex), non-exercised mdx (MDX-N.E.), exercised mdx (MDX-Ex) and exercised udx (UDX-Ex).
Mice sacrificed at specified histological time points are not included in Kaplan Meier survival curve.
Table 1 Absolute values (mean ± SD) of blood flow (BF), blood volume (BV), and standardized uptake value (SUV) for
each experimental group at baseline
Blood Flow (BF) Blood Volume (BV) Standardized Uptake Value (SUV)
Wild-type (w.t.) 33.85 ± 4.13 2.73 ± 0.49 0.38 ± 0.09
MDX (N.E) 42.33 ± 4.42 3.39 ± 0.48 0.36+0.08
MDX (Ex) 46.14 ± 4.27 3.54 ± 0.67 0.39 ± 0.1
UDX 54 ± 3.36 4.79 ± 0.55 0.46 ± 0.12
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relative to that occurring in mildly-affected mdx mice,
was evidenced by the predominance of centrally-located
nuclei (open arrow head) and the widespread presence
of inflammatory infiltrate within enlarged intercellular
space (arrow head) (Figure 5d(i)). Two weeks post-base-
line (8 weeks of age), non-exercised mdx mice still
exhibited centrally-located nuclei (open arrow head), as
well as modest inflammatory infiltrate (arrow head) (Fig-
ure 5b(ii)). Centrally-located nuclei were also observed
in exercised mdx and udx mice (open arrow head),
although most notable in both groups was the presence
of a marked inflammatory infiltrate amongst myofibers
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Figure 3 Normalized blood flow, NBF (a) and normalized blood volume, NBV (b) in hind limb muscle (HL). Data was collected over a 14-
16 week period from age 6 to 20-22 in exercised w.t. (W.T.-Ex), non-exercised mdx (MDX-N.E.), exercised mdx (MDX-Ex) and non-exercised udx
(UDX-N.E.) mice. Plotted values are means and standard deviations of NBF and NBV of surviving mice from each group. Significant differences (p
<0.05) were found at age 8 and 20 between: W.T.-Ex and MDX-N.E. (μ), W.T.-Ex and MDX-Ex (*), W.T.-Ex and UDX-N.E.(ψ), MDX-N.E. and UDX-N.E.
(≏), MDX-N.E. and MDX-Ex (j).
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(arrow head) (Figure 5c and 5d(ii)), and by the occa-
sional appearance of mineralized tissue (Figure 5c(ii),
thin arrow).
Intermediate and Late changes in perfusion, metabolism
and histology following exercise
In healthy exercised w.t. mice, NBF, NBV and NSUV in
the HL musculature did not change significantly over
the duration of the study (Figure 3 & Figure 4). In the
HL musculature of non-exercised mdx mice, however, a
progressive decline in all three imaging biomarkers was
observed: NBF (Figure 3a), NBV (Figure 3b) and NSUV
(Figure 4), relative to their respective peak values at 8
weeks of age. Similar, albeit greater, declines in all three
imaging biomarkers were observed in both exercised
mdx mice and non-exercised udx mice. Importantly,
these declines appear to reflect the disease state of each
model, with mildly-affected mdx mice being intermedi-
ate to healthy w.t. mice and severely-affected udx mice;
as expected, a greater decline is observed in exercised
mdx mice relative to their non-exercised litter mates.
As illustrated in Figure 5, analysis of H&E-stained sec-
tions of GMs harvested from either non-exercised or
exercised mdx mice at their endpoint revealed that
many myofibers now exhibit a healthy wild-type pheno-
type; specifically, eccentrically-located nuclei, rather
than centralized nuclei, predominate (open arrow head
in Figure 5b and 5c(iii & iv)). As further evidence of
this, by 22 weeks of age, there was only a mild inflam-
matory infiltrate in the exercised group and no visible
inflammatory infiltrate in the non-exercised group. In
udx mice, in comparison, myofibers exhibited advanced
atrophy with ongoing myofibrillar degeneration, and
mixed with marked inflammatory infiltrate (Figure 5d
(iii & iv).
Discussion
Muscle degeneration in DMD occurs due to mutations
in or a loss of dystrophin [1,2] from the sarcolemmal
glycoprotein membrane complex, and results in muscle
fragility, contraction-induced damage, necrosis, and
inflammation [3,4,11]. Inflammatory and immune pro-
cesses are now believed to be particularly important
during early disease progression, perhaps being initiated
via aberrant signaling in dystrophic sarcolemma [28-35].
However, while cellular events such as these are typi-
cally analyzed histologically, their use as effective indices
to monitor the progression of myopathy in dystrophic
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Figure 4 Normalized SUVs (NSUV) of 18F-FDG in hind limb muscle (HL). Data was collected over a 14-16 week period from age 6 to 20-22
in exercised w.t. (W.T.-Ex), non-exercised mdx (MDX-N.E.), exercised mdx (MDX-Ex) and non-exercised udx (UDX-N.E.) mice. Plotted values are
means and standard deviations of normalized SUV of surviving mice 23 from each group. Significant differences (p<0.05) are observed at week 8
and 20 between: W.T.-Ex and UDX –N.E. (ψ), MDX-Ex and UDX-N.E.(π), and MDX-N.E and UDX-N.E. (_); and, at week 4 between: W.T.-Ex and MDX-
Ex (*), and MDX-N.E. and MDX-Ex ().
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muscle is limited by an inability to longitudinally assess
them, and in a non-invasive manner. In the present
study, we conducted DCE-CT and PET scanning to
demonstrate the utility of non-invasive imaging biomar-
kers to longitudinally assess muscle regeneration/degen-
eration in two murine models of DMD.
Over the years, there has been some debate as to the
validity of using various murine models for studies of
DMD. To date, the mdx mouse model is the best char-
acterized, with gene expression profiles overlapping con-
siderably with humans [36]. More recent studies have
further shown that, as in DMD patients, both
sarcolemmal stabilization and contractile mechanisms
are impaired in myofibers isolated from mdx mice [37].
As there are many molecular aspects common to both
the mdx mouse and DMD patients, there is a strong
rationale for the use of the mdx mouse model in DMD
studies. There are, however, important differences
between the mdx mouse model and patients [38,39];
indeed initial disease onset in mdx mice occurs at ~3
weeks of age [40], The process of degeneration in mdx
skeletal muscles wanes shortly thereafter, by ~ 4 weeks,
at which time muscle regeneration predominates [40].
These cycles of muscle degeneration/regeneration are
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50 microns
(i)
50 microns
(iii)
Week 8
(ii)
50 microns
Endpoint
(iv)
50 microns
40x
N = 3
Baseline 
(i)
50 microns
Week 14
(iii)
50 microns
Endpoint
(iv)
50 microns
Week 8
(ii)
50 microns
MDX (N.E)
MDX (Ex) 40xN = 3
Baseline 
(i)
50 microns
Week 8
(ii)
50 microns
Week 14
(iii)
50 microns
Endpoint
(iv)
50 microns
UDX (N.E) 40xN = 3
Week 8
(ii)
50 microns
Endpoint
(iv)
50 microns
Week 14
(iii)
50 microns
Baseline 
(i)
50 microns
(a) (b)
(c) (d)
Figure 5 H&E-stained sections of gastrocnemius muscles (GMs). H&E-stained sections of gastrocnemius muscles (GMs) isolated from: (a)
wild-type (w.t.) mice at (i) baseline (6 weeks old), (ii) week 8, (iii) week 14, and (iv) at the termination of the study (20-22 weeks of age).
Pathology is described in the text. Legend: solid arrow, points to eccentrically-located nuclei in myofibers; (b) non-exercised mdx at (i) baseline,
(ii) week 8, (iii) week 14, and (iv) at the termination of the study. Legend: open arrowhead points to centrally-located nuclei in myofibers; closed
arrowhead points to inflammatory infiltrate, solid arrow points to eccentrically-located nuclei in myofibers; (c) exercised mdx mice at (i) baseline,
(ii) week 8, (iii) week 14, and (iv) at the termination of the study. The pathology observed in each group and at each time are described in the
text. Legend: solid arrow points to eccentrically-located nuclei; open arrowhead points to centrally-located nuclei in myofibers; closed arrowhead
points to inflammatory infiltrate; and thin solid arrow points to a mineralized lesion; (d) non-exercise udx mice at (i) baseline, (ii) week 8, (iii)
week 14, and (iv) at the termination of the study. Legend: open arrowhead points to centrally-located nuclei in myofibers; closed arrowhead
points to inflammatory infiltrate.
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suppressed by ~ age 3-4 months, but continues at low
levels for the remainder of the mouse’s lifetime [40],
thereby producing the mild phenotype well-associated
with the mdx model. Importantly, the imaging of bio-
markers conducted in the present study substantiates
these reports. The weak phenotype in mdx mice is
believed to be attributed, at least in part, to an upregula-
tion of utrophin (a homolog of dystrophin) in the sarco-
lemmal DGC, and compensatory mechanisms for the
loss of functional dystrophin [41]. Thus, the mdx:utrn-/-
(udx) mouse model, in comparison, exhibits a far greater
degree of muscle pathogenesis than that observed in
mdx mice, closely paralleling the human condition [42].
Indeed, severely affected udx mice in our study exhib-
ited progressive myofiber degeneration, with little repair
throughout the duration of the study.
Previous studies have reported the use of enforced
treadmill running to exacerbate muscle pathogenesis in
mdx mice [19]. Exercise-induced myofiber damage has
been further correlated with decreased expression of
hormones such as IGF-1 and myogenic transcription
factors such as Myo-D, which, in turn, contribute to the
degenerative state [43]. More recently, several studies
have concluded that voluntary exercise may be, in fact,
be beneficial [44-47]. In the present study, we used an
involuntary treadmill running protocol, although the
regime was not eccentric; as such, we were uncertain
whether we would indeed exacerbate muscle pathogen-
esis or slow disease progression. We observed little dif-
ference histologically between mdx mice exercised via
involuntary, uphill running and their non-exercised lit-
termates; at baseline to 2 weeks-post we observed, in
both groups, the presence of numerous centrally-located
nuclei and inflammatory infiltrate. Subsequent staining
from 8 weeks-post through to the termination of the
study demonstrated, in both exercised and non-exer-
cised mdx mice, the presence of eccentrically-located
nuclei and indicating that once-damaged muscle was
reverting to a healthy wild-type phenotype. Traditional
histology, however, tends to suffer from a sampling
issue, as only a small fraction of tissue is analyzed but
provides extremely high spatial resolution. In compari-
son, in vivo functional imaging, as presented in this
study, permits measurement of muscle perfusion, blood
volume and metabolic rate over the entire muscle mass,
thus avoiding the above-mentioned sampling problem.
We did, in fact, demonstrate that the uphill running
regime used in our study was sufficient to induce
changes in blood flow, blood volume and glucose meta-
bolism, and that these changes appear to correlate with
the severity of the disease state in each group of mice.
More specifically, we observed a transient increase in
blood flow, blood volume, and glucose uptake in mdx
mice 2 weeks-post (both exercised and unexercised),
relative to healthy wild-type control mice. Furthermore,
we were now able to distinguish between exercised mdx
and non-exercised mdx mice, with greater increases in
blood flow, blood volume and glucose metabolism being
exhibited by the former group. We suggest that these
transient increases in perfusion and metabolism in both
non-exercised and exercised mdx groups reflect active
cycles of degeneration/regeneration and a moderate
exacerbation of muscle pathogenesis, respectively. We
believe that the greatest increase in blood flow, blood
volume and glucose metabolism observed in udx mice is
likely due to the severity of pathogenesis and inflamma-
tion in these mice. These conclusions were supported
by histological findings. Given reports that cycles of
degeneration/regeneration wane at ~ 3-4 months of age
in mdx mice [40], we were not surprised to have
observed a subsequent progressive decrease in blood
flow, blood volume and metabolism. Importantly, our
imaging of biomarkers enabled us in the present study
to detect differences between exercised mdx mice and
their non-exercised littermates, with the former exhibit-
ing a greater decline in each biomarker. Not surpris-
ingly, still greater declines in all imaging biomarkers was
observed in severely-affected udx mice, findings that
were, again, supported by our histological findings. To
the best of our knowledge, there is no satisfactory
method, to date, to account for the vastly different
scales of resolution and sampling between traditional
histology and in vivo functional imaging when the two
types of results are compared. Nevertheless, we are con-
fident that the qualitative histological findings illustrated
in this study do indeed support our hemodynamic and
metabolic measurements as functional imaging methods
for the assessment of physiologic changes in degenerat-
ing/regenerating muscle in vivo.
There are several limitations in our study. Firstly, in
each DCE-CT study, an approximate 26 mSv effective
dose was administered to individual mice. Since wild-
type mice did not exhibit overt muscle damage, primary
radiation damage in dystrophic mice can be ruled out.
However, it is possible that the radiation administered
may have compounded ischemic and inflammatory
effects to exacerbate damage observed in both mdx and
udx mouse models. A second limitation of our study
results from the exercise protocol; exercised animals
were included to assess the effects of chronic damage in
the DMD models, yet because exercise was induced
before imaging scans, acute effects of exercise might
confound our imaging findings. We believe, however,
that at the time of scanning, which was typically 30
minutes after exercise, the effects of exercise would be
limited. In addition, since each animal was serially stu-
died using the same protocol, with the results of each
animal being normalized with respect to its own
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baseline, the residual effects of exercise would be fac-
tored out in inter- and intra-animal comparisons.
Conclusions
In summary, the present study clearly demonstrates that
non-invasive imaging of biomarkers accurately reflects
the disease state (ie., mdx mice are intermediate in dis-
ease severity to healthy wild-type mice and severely-
affected udx mice). Furthermore, imaging of biomarkers
allows us to delineate changes in muscle regeneration/
degeneration beyond that achievable with traditional his-
tological analyses of DMD, ie., changes in blood flow,
blood volume and glucose metabolism between non-
exercised and exercised groups of mdx mice. This could
have enormous implications for much needed studies
examining the mechanisms of DMD pathology that may
improve or worsen as a result of exercise. Importantly,
these technologies can potentially be translated to the
clinic as an alternative to invasive procedures. Further-
more, our findings may now serve as a baseline for com-
parison with cell and gene therapeutics aimed at
improving the quality of life for patients, and/or finding
a cure for those affected with DMD or other neuromus-
cular diseases.
Appendix
Tracer Kinetic Modeling
Muscle blood flow (perfusion) and blood volume maps
were calculated by means of the tracer kinetic model
first described by Johnson and Wilson [48]. St Lawrence
and Lee derived the adiabatic approximation solution
which simplifies the calculation of perfusion and other
related functional parameters in tissue such that it is
independent of the relative magnitude of the permeabil-
ity surface area (PS) product of the capillary endothe-
lium to contrast agent to perfusion [22]. Since
capillaries in muscle are permeable to contrast, the
model divides muscle into two principal spaces; the
intravascular space (IVS) and the extra-vascular space
(EVS), which are separated by the permeable capillary
endothelium [48]. The model uses three basic assump-
tions to arrive at a solution. First, the permeable capil-
lary endothelium allows bidirectional diffusion of
contrast agent between EVS and IVS. Second, in the
capillaries there is an axial concentration gradient of
contrast but the radial concentration gradient is
assumed to be negligible. Third, within the EVS the tra-
cer concentration is assumed to have a homogeneous
spatial distribution (i.e. EVS is a compartment). The
adiabatic approximation, as discussed by St. Lawrence
and Lee [22]. assumes that the EVS contrast concentra-
tion is changing slowly (i.e. in a quasi-steady state) rela-
tive to the rate of change of concentration in the IVS
(capillaries). Using the adiabatic approximation, the
impulse residue function [22], H (t), can be represented
as:
H(t) =
⎧⎨
⎩
1 0 ≤ t ≥ Tc
Ee
[
−
(EF
Vc
)
(t−Tc)
]
t > Tc
⎫⎬
⎭ (1)
where T c is the capillary transit time and F is blood
flow so that blood volume is FTc according to the Cen-
tral Volume Principle [49], E is the extraction fraction
of contrast and Ve is the distribution volume of contrast
in the EVS. E relates to the PS of muscle capillaries via
the following relationship [50]:
E = 1 − e
⎛
⎝PS
F
⎞
⎠ (2)
If the concentration (enhancement) of contrast (arter-
ial) input to the muscle, Ca(t), is known, then the mea-
sured muscle contrast enhancement curve, Q (t), can be
calculated as the convolution of Ca(t) and H (t):
Q (t) = F · Ca (t) ∗H (t) (3)
where * is the convolution operator. The validity of
equation 3 assumes that muscle blood flow is constant
and Q (t) is linear with respect to Ca(t).
The lower limbs are supplied by two common iliac
arteries, Ca(t) was obtained from the DCE-CT images
with a ROI placed in one of the those arteries. From
each 2 × 2 pixel block in the DCE-CT images, the
muscle contrast enhancement curves, Q(t), was also
obtained. Deconvolution between Ca(t) and Q(t) with
the CT Perfusion software (GE Healthcare) gave H(t),
from the latter muscle blood flow (perfusion) and
blood volume for the pixel block in question were
derived with Eqs (1)-(3). Functional maps of muscle
perfusion and blood volume were generated by
repeating the deconvolution process for each pixel
block.
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